WASHINGTON – Today,
the Senate Judiciary Committee advanced twenty-four judicial nominations, as
well as five bipartisan bills to help lower prescription drug prices to the
full Senate.
“The judicial
nominees advanced to the full Senate today build upon our Committee’s progress
confirming highly qualified judges,” said Senate Majority Whip Dick Durbin
(D-IL), Chair of the Senate Judiciary Committee. “I look forward to my
colleagues in the full Senate having the opportunity to vote to confirm these
nominees who will bring balance and impartiality to our justice system.”
Durbin continued, “The
legislation we advanced today will help lower prescription drug costs for
families and get crucial medications to those who need it – whether it’s from
improving coordination between agencies, bringing generic drugs to market more
quickly, or fostering competition in the pharmaceutical industry. Americans
should not have to choose between filling a prescription and buying groceries
or paying utility bills. Particularly, I appreciate that each bill advanced
today was bipartisan, exemplifying the potential for our Committee to continue
working together to make progress on pocketbook issues facing the American
people.”
The following
nominees advanced with the indicated vote totals:
- Nancy
G. Abudu, to be United States Circuit
Judge for the Eleventh Circuit: 11-10;
- Rachel
Bloomekatz, to be United States Circuit
Judge for the Sixth Circuit: 11-10;
- Anthony
Devos Johnstone, to be United States Circuit
Judge for the Ninth Circuit; 11-10;
- Julie
Rikelman, to be United States Circuit
Judge for the First Circuit: 11-10;
- Robert
Stewart Ballou, to be United States District
Judge for the Western District of Virginia: 16-5;
- Nusrat
Jahan Choudhury, to be United States District
Judge for the Eastern District of New York: 11-10;
- Jessica
G.L. Clarke, to be United States District
Judge for the Southern District of New York: 11-10;
- Todd
E. Edelman, to be United States District
Judge for the District of Columbia: 11-10;
- Kymberly
Kathryn Evanson, to be United States District
Judge for the Western District of Washington: 12-9;
- Gordon
P. Gallagher, to be United States District
Judge for the District of Colorado: 14-7;
- Jonathan
James Canada Grey, to be
United States District Judge for the Eastern District of Michigan: 13-8;
- Dale
E. Ho, to be United States District
Judge for the Southern District of New York: 11-10;
- Myong
J. Joun, to be United States District
Judge for the District of Massachusetts: 12-9;
- Kenly
Kiya Kato, to be United States District
Judge for the Central District of California: 11-10;
- Julia
E. Kobick, to be United States District
Judge for the District of Massachusetts: 11-10;
- Colleen
R. Lawless, to be United States District
Judge for the Central District of Illinois: 14-7;
- Rita
F. Lin, to be United States District
Judge for the Northern District of California: 12-9;
- Natasha
Merle, to be United States District
Judge for the Eastern District of New York: 11-10;
- P.
Casey Pitts, to be United States District
Judge for the Northern District of California: 12-9;
- Ramon
Ernesto Reyes, to be United States District
Judge for the Eastern District of New York: 11-1;
- Andrew
G. Schopler, to be United States District
Judge for the Southern District of California: 15-6;
- James
Edward Simmons, Jr., to be
United States District Judge for the Southern District of California:
13-8;
- Arun
Subramanian, to be United States District
Judge for the Southern District of New York: 16-5; and
- Hernan D. Vera, to be United States District
Judge for the Central District of California: 11-10.
The following
bills advanced to the full Senate by voice vote:
- S.
79, Interagency Patent Coordination and Improvement Act of 2023 to amend title 35, United States Code, to establish an
interagency task force between the United States Patent and Trademark
Office and the Food and Drug Administration for purposes of sharing
information and providing technical assistance with respect to patents.
The bill was introduced by Senators Durbin and Tillis and is cosponsored
by Senators Grassley, Coons, Welch, and Feinstein.
- S.
113, Prescription Pricing for the People Act of 2023, as amended, to require the Federal Trade Commission
to study the role of intermediaries in the pharmaceutical supply chain and
provide Congress with appropriate policy recommendations. The bill was
introduced by Senators Grassley and Cantwell and is cosponsored by
Senators Blumenthal, Lankford, Blackburn, Tuberville, Tillis, Capito,
Braun, Boozman, Welch, Coons, Hirono, and Feinstein.
- S.
142, Preserve Access to Affordable Generics and Biosimilars Act, as amended, to prohibit brand name drug companies from
compensating generic drug companies to delay the entry of a generic drug
into the market, and to prohibit biological product manufacturers from
compensating biosimilar and interchangeable companies to delay the entry
of biosimilar biological products and interchangeable biological products.
The bill was introduced by Senators Klobuchar and Grassley and is
cosponsored by Senators Durbin, Cramer, Blumenthal, Kelly, Van Hollen,
Booker, Ossoff, and Ernst.
- S.
148, Stop STALLING Act, as
amended, to enable to Federal Trade Commission to deter filing
of sham citizen petitions to cover an attempt to interfere with
approval of a competing generic drug or biosimilar, to foster competition,
and facilitate the efficient review of petitions filed in good faith
to raise legitimate public health concerns. The bill was introduced by
Senators Klobuchar and Grassley and is cosponsored by Senators Durbin,
Braun, Blumenthal, Cruz, Booker, and Ossoff.
- S.
150, Affordable Prescriptions for Patients Act of 2023 to amend the Federal Trade Commission Act to prohibit
product hopping. The bill was introduced by Senators Cornyn and Blumenthal
and is cosponsored by Senators Grassley, Durbin, Cruz, and Klobuchar.
-30-